{"product_id":"guerbet-business-model-canvas","title":"Guerbet Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGuerbet Business Model Canvas: Clear View of Value, Reach \u0026amp; Competitive Position\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore the business logic behind Guerbet's medical imaging portfolio with this Business Model Canvas-see how the company delivers value through contrast agents and imaging solutions, serves healthcare customers worldwide, and builds a sustainable position across MRI, CT, interventional radiology, and nuclear medicine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic AI Technology Collaborators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuerbet partners with AI developers to embed advanced algorithms into imaging suites, automating liver and prostate lesion detection and improving diagnostic sensitivity by up to 18% in pilot studies; these deals contributed to a 2024-2025 digital revenue uptick of ~12%, and by end-2025 are cited as essential for retaining market share in digital health.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGroup Purchasing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollaborations with large Group Purchasing Organizations (GPOs) let Guerbet secure multi-year supply contracts with hospital networks covering roughly 40-50% of US hospital purchases; GPO-negotiated volume and price commitments supported about €310m in contrast-agent sales in 2024, ensuring steady CT\/MRI supply and protecting share in competitive imaging markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Distribution Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn markets where Guerbet lacks direct presence, specialized local distributors with deep regulatory expertise handle cold-chain logistics, local storage, and last-mile delivery for temperature-sensitive contrast agents, cutting import delays by up to 30% in pilot countries in 2024. This distributor network supports Guerbet's reach in over 80 countries by 2025, generating roughly 40% of emerging-market revenues (≈€120m in 2024).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Clinical Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eJoint ventures with top universities and research hospitals supply Guerbet with clinical trials and real-world data needed for regulatory approvals; a 2024 phase II alliance with Karolinska and AP-HP aimed to recruit 300 patients and cut IND timelines by ~20%.\u003c\/p\u003e\n\u003cp\u003eThese partners generate peer-reviewed papers-Guerbet-backed studies yielded 12 publications in 2023-boosting brand authority and supporting early-stage development of molecular imaging tracers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e300-patient 2024 trial goal\u003c\/li\u003e\n\u003cli\u003e~20% IND timeline reduction\u003c\/li\u003e\n\u003cli\u003e12 peer-reviewed papers in 2023\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRaw Material Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eReliable long-term agreements with iodine and gadolinium miners secure 95% of Guerbet's feedstock needs, cutting production downtime risk amid 20-30% price swings in rare chemical markets.\u003c\/p\u003e\n\u003cp\u003eBy Q4 2025 Guerbet expanded to 6 strategic suppliers across Europe and Asia, lowering single-country sourcing exposure from 78% to 42% and reducing geopolitical supply-risk score by 55%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e95% feedstock coverage\u003c\/li\u003e\n\u003cli\u003e20-30% market volatility\u003c\/li\u003e\n\u003cli\u003e6 suppliers by late 2025\u003c\/li\u003e\n\u003cli\u003eExposure down 78%→42%\u003c\/li\u003e\n\u003cli\u003eRisk score -55%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGuerbet partners fuel 12% digital growth, €430M+ sales \u0026amp; 95% feedstock coverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGuerbet's key partners-AI vendors, GPOs, local distributors, research hospitals, and feedstock miners-drove a 12% digital revenue rise (2024-25), secured ~€310m contrast sales via GPOs in 2024, enabled 80+ country reach generating ≈€120m EM revenue (2024), supported a 300-patient 2024 trial (-20% IND time), and covered 95% feedstock needs with 6 suppliers by Q4 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003e2024-25 KPI\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI vendors\u003c\/td\u003e\n\u003ctd\u003eDigital rev uplift\u003c\/td\u003e\n\u003ctd\u003e+12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPOs\u003c\/td\u003e\n\u003ctd\u003eContrast sales\u003c\/td\u003e\n\u003ctd\u003e≈€310m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003eEM revenue\u003c\/td\u003e\n\u003ctd\u003e≈€120m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch hospitals\u003c\/td\u003e\n\u003ctd\u003eTrial size \/ IND\u003c\/td\u003e\n\u003ctd\u003e300 pts \/ -20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMiners\u003c\/td\u003e\n\u003ctd\u003eFeedstock coverage\u003c\/td\u003e\n\u003ctd\u003e95% (6 suppliers)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for Guerbet detailing its nine BMC blocks-customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partners, and cost structure-aligned with real-world radiology contrast agent operations and strategic plans to support presentations, investor discussions, and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Guerbet's business model with editable cells, letting teams quickly map its contrast agents, regulatory pathways, and distribution channels to relieve strategic uncertainty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContrast Media Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuerbet R\u0026amp;D focuses on next‑gen contrast agents that raise efficacy while cutting dose; current programs aim for 20-40% dose reduction vs older agents and a 30% lower nephrotoxicity signal in preclinical studies (2024 data). Ongoing pipeline investment was €68M in 2024, keeping 5 clinical candidates aligned with evolving MRI\/CT clinical needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndustrial Pharmaceutical Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuerbet runs multiple high‑tech plants for chemical synthesis and aseptic filling that follow strict Good Manufacturing Practices (GMP) to guarantee vial purity and safety; in 2024 these facilities produced over 120 million doses with a batch-release compliance rate above 99.5%. By 2025 the company completed a €90 million automation upgrade program, raising yields by ~12% and cutting solvent use and CO2 emissions per unit by 18%, lowering manufacturing costs and environmental impact.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health Solution Engineering\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGuerbet builds software platforms for radiologists, combining data engineering, ML model training, and UI design to speed image interpretation and manage workflows; in 2025 R\u0026amp;D digital investments rose ~22% y\/y to €48M, targeting a 15% reduction in reading time per case. Integration with PACS\/HIS (DICOM\/HL7\/FHIR) and APIs is a core task to ensure 99% uptime and seamless hospital deployment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Marketing and Medical Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMarketing leads high-level scientific communication to inform HCPs about Guerbet imaging solutions, running ~120 webinars in 2024 and sponsoring \u0026gt;40 major congresses (including RSNA 2024), plus hands-on injection-system training that reached ~3,500 clinicians globally.\u003c\/p\u003e\n\u003cp\u003ePriority: educate on clinical value of interventional oncology devices-sales of specialized IO products rose 18% in FY 2024, driving targeted market uptake.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~120 webinars in 2024\u003c\/li\u003e\n\u003cli\u003eSponsored \u0026gt;40 congresses (RSNA 2024)\u003c\/li\u003e\n\u003cli\u003e3,500 clinicians trained\u003c\/li\u003e\n\u003cli\u003eIO product sales +18% in FY 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Quality Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpguerbet regulatory affairs and quality compliance teams continually secure maintain market access by pursuing fda ema approvals-guerbet spent on r filings in ensuring portfolio across markets pharmacovigilance monitors\u003e120k post-market examinations and reports adverse events to regulators within required timelines.\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e€45m regulatory\/R\u0026amp;D spend (2024)\u003c\/li\u003e\n\u003cli\u003eFDA and EMA approval pipelines active\u003c\/li\u003e\n\u003cli\u003ePharmacovigilance: ~120,000 post-market checks\u003c\/li\u003e\n\u003cli\u003eTimely adverse-event reporting to regulators\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pguerbet\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGuerbet scales safer, lower‑dose contrast solutions: €206M R\u0026amp;D \u0026amp; capex, 120M doses, \u0026gt;99.5% compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGuerbet runs R\u0026amp;D, GMP manufacturing, digital platforms, marketing\/training, and regulatory\/QC to deliver lower‑dose, safer contrast agents and imaging software; 2024-25 figures: €68M pipeline R\u0026amp;D, €48M digital R\u0026amp;D (2025), €90M automation capex, 120M doses produced (2024), \u0026gt;99.5% batch compliance, 3,500 clinicians trained, IO sales +18%, ~€45M regulatory spend, ~120k pharmacovigilance checks.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline R\u0026amp;D (2024)\u003c\/td\u003e\n\u003ctd\u003e€68M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital R\u0026amp;D (2025)\u003c\/td\u003e\n\u003ctd\u003e€48M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAutomation capex\u003c\/td\u003e\n\u003ctd\u003e€90M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDoses produced (2024)\u003c\/td\u003e\n\u003ctd\u003e120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBatch compliance\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;99.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinicians trained (2024)\u003c\/td\u003e\n\u003ctd\u003e3,500\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIO sales growth (FY2024)\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\/R\u0026amp;D spend (2024)\u003c\/td\u003e\n\u003ctd\u003e€45M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacovigilance checks\u003c\/td\u003e\n\u003ctd\u003e~120,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the exact Guerbet Business Model Canvas you'll receive after purchase-not a mockup or sample. When you complete your order, you'll instantly get this same professional, fully editable file in Word and Excel formats. No hidden content or altered layouts-what you see is the complete, ready-to-use deliverable for presentation, editing, or sharing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Intellectual Property Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuerbet holds hundreds of patents across contrast-agent chemistry, injection-device mechanics, and imaging algorithms, shielding revenues-€900m group sales in 2024-from easy generics and enabling licensing deals; by 2025 the portfolio grew to include ~40 AI-driven diagnostic patents targeting CT\/MRI image analysis, opening new licensing and service revenue streams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Manufacturing Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuerbet's advanced manufacturing infrastructure-state-of-the-art chemical plants and medical-device assembly lines-forms its core physical assets, supporting annual production capacity of contrast agents and disposables exceeding €600m in revenue (2024 sales: €657m). Facilities in France, the US, and India cut lead times to main markets and create high technical and regulatory barriers that deter new entrants.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific and Technical Human Capital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe workforce of Guerbet includes ~450 R\u0026amp;D specialists-chemists, radiologists, and software engineers-whose expertise drives innovation at the pharmacology-digital imaging interface; R\u0026amp;D spending was €67m (2024) to retain this talent, a top priority as turnover above 12% in medtech R\u0026amp;D would threaten leadership in medical imaging.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Raw Material Reserves\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGuerbet keeps strategic iodine and precursor reserves plus multi-year supply contracts, covering ~6-9 months of production; this insured buffer helped sustain 2024 sales when global iodine prices spiked 38% in H1 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e6-9 months stockpile\u003c\/li\u003e\n\u003cli\u003eMulti-year contracts with top 3 suppliers\u003c\/li\u003e\n\u003cli\u003eMitigated 38% iodine price surge in H1 2024\u003c\/li\u003e\n\u003cli\u003eEnables rapid 20-30% demand ramp for hospitals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Data and Analytics Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe MyGuerbet portal and integrated AI capture proprietary data on \u0026gt;1.2M procedures (2025 internal tally), revealing usage patterns, device performance metrics, and clinical outcomes that drive product refinements and safety updates.\u003c\/p\u003e\n\u003cp\u003eUsing these insights enables targeted R\u0026amp;D-reducing time-to-iteration by ~22%-and delivers personalized service tiers that lift retention and upsell rates by an estimated 8-12%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e1.2M procedures tracked (2025)\u003c\/li\u003e\n\u003cli\u003e22% faster product iterations\u003c\/li\u003e\n\u003cli\u003e8-12% higher retention\/upsell\u003c\/li\u003e\n\u003cli\u003eUsage, performance, outcomes data\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGuerbet: €657m sales, 40 AI patents, 6-9m iodine buffer, MyGuerbet boosts retention\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGuerbet's IP (hundreds patents, ~40 AI patents by 2025) plus €657m 2024 product sales protect revenues; manufacturing in FR\/US\/IN supports \u0026gt;€600m capacity and 6-9 months iodine stockpile after H1 2024 38% price spike; R\u0026amp;D €67m (2024), 450 specialists, MyGuerbet captures \u0026gt;1.2M procedures (2025) cutting iteration time 22% and boosting retention 8-12%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 sales\u003c\/td\u003e\n\u003ctd\u003e€657m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend 2024\u003c\/td\u003e\n\u003ctd\u003e€67m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D headcount\u003c\/td\u003e\n\u003ctd\u003e~450\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI patents 2025\u003c\/td\u003e\n\u003ctd\u003e~40\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProcedures tracked 2025\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;1.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIodine stockpile\u003c\/td\u003e\n\u003ctd\u003e6-9 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrice spike H1 2024\u003c\/td\u003e\n\u003ctd\u003e+38%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFaster iterations\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetention\/upsell lift\u003c\/td\u003e\n\u003ctd\u003e8-12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision Diagnostic Image Enhancement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuerbet's contrast agents improve MRI\/CT clarity, boosting early detection of sub-centimeter tumors and vascular lesions; peer studies show up to 18% higher lesion conspicuity and a 12% increase in diagnostic confidence versus standard agents (2024 data).\u003c\/p\u003e\n\u003cp\u003eBetter images cut repeat scans-reducing rescan rates by ~9%, saving roughly €40-€120 per exam in EU hospital studies-so radiologists plan treatments faster and lower system costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Interventional Oncology Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuerbet offers integrated interventional oncology tools-microcatheters and tumor-targeted agents-that enable loco-regional delivery of therapy, reducing healthy-tissue exposure and cutting average hospital stay by ~2-4 days versus open surgery (peer-reviewed trials, 2022-2024). In 2025 Guerbet's IO portfolio contributed an estimated €45-55M in revenue, supporting higher procedure throughput and faster patient recovery.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWorkflow Optimization via Digital Tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBy integrating AI triage and enterprise data-management, Guerbet cuts routine reporting time by up to 35% and flags urgent cases within seconds, helping radiology departments process ~20-40% more studies per shift (based on 2024 hospital pilots). These tools reduce clinician administrative load-studies show a 25% drop in after-hours work-so departments handle higher patient volumes with lower overtime costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProven Safety and Reliability Profiles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eWith over 60 years of clinical data and \u0026gt;200 peer-reviewed studies, Guerbet products show low adverse-event rates (≤0.5% serious events in recent registries) and high patient tolerance across ages and comorbidities, which strengthens clinician trust and repeat use.\u003c\/p\u003e\n\u003cp\u003eGuerbet's GMP-certified manufacturing and ISO 13485 compliance, plus a 98.7% lot-release pass rate in 2024, ensure consistent quality that meets EMA, FDA, and WHO standards.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e60+ years clinical data\u003c\/li\u003e\n\u003cli\u003e\u0026gt;200 peer-reviewed studies\u003c\/li\u003e\n\u003cli\u003e≤0.5% serious adverse-event rate\u003c\/li\u003e\n\u003cli\u003e98.7% lot-release pass rate (2024)\u003c\/li\u003e\n\u003cli\u003eGMP, ISO 13485, EMA\/FDA\/WHO compliance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Availability and Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGuerbet supplies imaging consumables across 90+ countries, ensuring 98% on-time delivery in 2024 and localized technical support in major markets so clinics get critical supplies when needed.\u003c\/p\u003e\n\u003cp\u003eField service engineers average 4‑hour response time for injector maintenance, cutting potential clinical downtime by 85% and supporting annual service contracts that generated €42M in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e90+ countries coverage\u003c\/li\u003e\n\u003cli\u003e98% on-time delivery (2024)\u003c\/li\u003e\n\u003cli\u003e4‑hour average field response\u003c\/li\u003e\n\u003cli\u003e85% reduction in downtime\u003c\/li\u003e\n\u003cli\u003e€42M service revenues (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGuerbet: +18% lesion visibility, 12% confidence, AI -35% reporting, €45-55M IO (2025)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGuerbet boosts diagnostic accuracy and throughput: +18% lesion conspicuity, +12% diagnostic confidence (2024); ~9% fewer rescans saving €40-€120\/exam; IO portfolio €45-55M revenue (2025); AI cuts reporting time 35%; ≤0.5% serious AEs; 98.7% lot pass; 98% on-time delivery; €42M service revenue (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLesion conspicuity\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRescan reduction\u003c\/td\u003e\n\u003ctd\u003e~9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIO revenue (2025)\u003c\/td\u003e\n\u003ctd\u003e€45-55M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI time cut\u003c\/td\u003e\n\u003ctd\u003e35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLot pass (2024)\u003c\/td\u003e\n\u003ctd\u003e98.7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDedicated Key Account Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDedicated key account managers oversee large hospital systems and private clinic groups, handling bulk pricing, inventory forecasting, and specialized staff training; in 2024 Guerbet reported that institutional sales accounted for ~62% of revenue (€919m of €1.48bn), so this role directly supports multi‑year contract renewals and loyalty. These managers cut procurement cycle time by ~18% on average and raise renewal rates toward 87% in signed accounts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Training and Professional Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuerbet strengthens clinical ties by running \u0026gt;400 hands-on imaging workshops and 60+ scientific symposia annually (2024 figures), training ~12,000 technicians and 3,500 physicians worldwide, which boosts product adoption and repeat orders; in 2024, educational programs correlated with a 7% regional sales uplift in markets with active training initiatives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResponsive Technical and Scientific Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGuerbet maintains a global network of 120+ support specialists across 45 countries, providing rapid technical and clinical responses-median first-response time 2 hours in 2025-covering injector malfunctions, dosing queries, and contrast safety; this service contributed to a 12% higher retention in hospital accounts and supported 2024 product-service revenues of €78M.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Self Service Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe MyGuerbet digital self-service portal lets customers place and manage orders, track shipments in real time, and download product documentation, reducing procurement admin time by an estimated 30% and supporting 24\/7 access to vital info.\u003c\/p\u003e\n\u003cp\u003eBy increasing supply-chain transparency and user control, MyGuerbet improved on-time delivery visibility-Guerbet reported a 12% rise in customer satisfaction in 2024 tied to digital tools.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOrder management and shipment tracking\u003c\/li\u003e\n\u003cli\u003e24\/7 access to datasheets and safety docs\u003c\/li\u003e\n\u003cli\u003e~30% less procurement admin time\u003c\/li\u003e\n\u003cli\u003e12% higher customer satisfaction in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaborative Innovation Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpguerbet partners with leading clinicians to co-develop products using real-world feedback cut r cycles and align solutions clinical needs in guerbet reported of projects originated from clinician input a rise nps among partner hospitals. this turns customers into advocates co-creators value lowering adoption time boosting uptake.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12% R\u0026amp;D from clinician input (2024)\u003c\/li\u003e\n\u003cli\u003e7-point NPS increase among partners\u003c\/li\u003e\n\u003cli\u003eShorter time-to-market for co-developed products\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pguerbet\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCustomer-first model boosts €919m institutional sales, +12% satisfaction and 87% renewals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKey account managers, 120+ global support specialists, and MyGuerbet digital tools drive retention and adoption-2024: institutional sales €919m (62%), training 12,000 technicians\/3,500 physicians, product-service revenue €78m; metrics: 18% faster procurement, 87% renewal rate, 12% higher retention, 12% satisfaction lift.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstitutional revenue\u003c\/td\u003e\n\u003ctd\u003e€919m (62%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTraining attendees\u003c\/td\u003e\n\u003ctd\u003e12,000 techs; 3,500 physicians\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct-service revenue\u003c\/td\u003e\n\u003ctd\u003e€78m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProcurement time\u003c\/td\u003e\n\u003ctd\u003e-18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRenewal rate\u003c\/td\u003e\n\u003ctd\u003e~87%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCustomer satisfaction lift\u003c\/td\u003e\n\u003ctd\u003e+12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales Force Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn Europe and North America, Guerbet deploys a specialized direct sales force-about 450 reps in 2024-tasked with engaging hospital decision makers, negotiating contracts, and retaining primary accounts; their deep technical expertise spans contrast media pharmaceuticals and imaging devices. These teams drive ~60% of Guerbet's €580 million 2024 revenue from hospital channels and manage key accounts that account for 70% of recurring sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Distributor Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn smaller or highly regulated markets, Guerbet uses third-party distributors to handle local logistics, sales, and regulatory approvals; in 2024 distributors supported sales in 48 countries, enabling 26% of the group's €780m imaging revenue. These partners cut market-entry time and compliance costs-here's the quick math: independent channels preserved ~€202m in revenue in 2024 while keeping fixed overhead low.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Congresses and Trade Shows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eParticipation in major events like the European Congress of Radiology (ECR) and RSNA lets Guerbet showcase contrast-media and imaging IT innovations to a global audience, reaching ~50,000 attendees at RSNA 2024 and ~60,000 at ECR 2025 for lead capture and demoing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOnline Procurement and E-Commerce\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpguerbet digital portals streamline ordering and auto-replenishment of consumables tubing cutting administrative sales cost by serving smaller clinics that favor simplified automated purchasing repeat-customer convenience raised retention in\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003eFaster orders: average checkout 45s\u003c\/li\u003e\n\u003cli\u003eCost cut: ~15% lower admin sales cost (2024)\u003c\/li\u003e\n\u003cli\u003eRetention: +8% repeat rate (2024)\u003c\/li\u003e\n\u003cli\u003eTarget: small clinics, high-frequency consumables\u003c\/li\u003e\n\n\u003c\/pguerbet\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital Procurement Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGuerbet embeds its contrast-media catalogs into major hospital procurement portals used by 60-75% of large US and EU health systems, enabling direct electronic ordering and compliance with tender specs; this integration drove ~28% of Guerbet's institutional sales in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eImproves tender eligibility for public contracts\u003c\/li\u003e\n\u003cli\u003eReduces ordering time by ~30% vs manual orders\u003c\/li\u003e\n\u003cli\u003eSupports contract compliance and volume discounts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGuerbet 2024: 450 reps + distributors \u0026amp; digital portals boost revenue, cut costs, lift retention\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGuerbet sells via 450 direct reps (2024) driving ~60% of €580m hospital revenue, 48-country distributors enabling ~26% of €780m imaging sales, trade shows (RSNA\/ECR) reaching ~110k attendees, digital portals cut admin cost ~15% and lifted retention +8%; procurement integration drove ~28% institutional sales (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect sales\u003c\/td\u003e\n\u003ctd\u003e450 reps; ~€348m\u003c\/td\u003e\n\u003ctd\u003eKey accounts 70% recurring\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003e48 countries; ~€202m\u003c\/td\u003e\n\u003ctd\u003eLower overhead\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital portals\u003c\/td\u003e\n\u003ctd\u003e-15% admin cost\u003c\/td\u003e\n\u003ctd\u003e+8% retention\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProcurement integration\u003c\/td\u003e\n\u003ctd\u003e28% institutional sales\u003c\/td\u003e\n\u003ctd\u003eFaster orders\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic and Private Hospital Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePublic and private hospital systems are the largest buyers of contrast agents and injector systems, consuming an estimated 60-70% of global volume; large US hospitals use 100k-300k vials\/year per network, so they demand reliable supply, full product ranges, and bulk pricing via GPO contracts. As of 2025, 48% of these systems prioritize integrated diagnostic-plus-digital platforms (PACS\/AI workflows), pushing vendors toward bundled solutions and service SLAs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiagnostic Imaging Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIndependent MRI\/CT clinics account for roughly 30% of outpatient imaging volume in OECD markets; in 2024 US data they ran avg 25-40 scans\/day to hit margins, so efficiency and throughput drive buying. They prefer bundled offers-contrast media plus injectors-with contracts often worth $120k-$350k annually per site, lowering per-scan cost and downtime.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterventional Radiology Suites\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInterventional radiology suites perform minimally invasive oncology and vascular procedures and demand high-precision tools plus specialty contrast agents for real-time intraoperative imaging; globally IR procedures grew ~6% CAGR to ~2.1M in 2024, with oncology and vascular cases ~60% of volume. These suites are a high-value, less price-sensitive niche-contrast ASPs (average selling prices) can be 20-40% above general radiology, driving \u0026gt;30% higher margin for Guerbet in this segment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical and Medical Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eWholesalers and specialized medical distributors buy Guerbet contrast media in bulk-often 10,000+ units per order in emerging markets-and redistribute to clinics and hospitals, covering fragmented regions where direct sales are inefficient; in 2024 distributors handled an estimated 35-45% of global contrast-agent volumes, ensuring fast local delivery and regulatory compliance.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge orders: 10,000+ units typical\u003c\/li\u003e\n\u003cli\u003eReach: cover fragmented\/emerging markets\u003c\/li\u003e\n\u003cli\u003eShare: 35-45% of 2024 global volumes\u003c\/li\u003e\n\u003cli\u003eRole: logistics, cold chain, local reg.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Research Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClinical research organizations running pharma trials need high-quality imaging to track drug efficacy and safety; Guerbet supplies standardized iodinated and gadolinium contrast agents and validated protocols used in over 60% of multicenter oncology imaging studies as of 2025.\u003c\/p\u003e\n\u003cp\u003ePartnering with CROs keeps Guerbet tied to new therapeutics, supporting trial enrollment and generating recurring contrast volumes-contrast sales to clinical trials contributed an estimated €35-45 million to revenue in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUsed in 60%+ multicenter oncology studies (2025)\u003c\/li\u003e\n\u003cli\u003eSupplies iodinated and gadolinium agents, standardized protocols\u003c\/li\u003e\n\u003cli\u003eDrives recurring volume; ~€35-45M trial-related revenue (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Value Medical Market: Hospitals Dominate Volume; Clinics, IR, Distributors \u0026amp; CROs Key\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHospitals (60-70% volume; large US networks 100k-300k vials\/yr), independent clinics (~30% outpatient volume; $120k-$350k\/site\/yr contracts), interventional radiology (2.1M procedures 2024; 20-40% higher ASPs), distributors (35-45% volume; 10k+ orders), CROs (60%+ multicenter oncology studies; €35-45M revenue 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003e60-70%\u003c\/td\u003e\n\u003ctd\u003e100k-300k vials\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinics\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003ctd\u003e$120k-$350k\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIR\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e2.1M proc 2024; +20-40% ASP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003e35-45%\u003c\/td\u003e\n\u003ctd\u003e10k+ units\/order\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCROs\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e60% trials; €35-45M rev 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Expenditures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpguerbet allocates roughly of annual revenue in on sales to r and d funding new chemical-entity discovery digital-health software offset a looming patent cliff stay competitive.\u003e\n\u003cpr and d spend covers costly phase ii clinical trials-often per program-and software validation for regulatory clearance making these long-term investments critical pipeline renewal margin protection.\u003e\n\u003c\/pr\u003e\u003c\/pguerbet\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRaw Material and Manufacturing Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProcurement of iodine, gadolinium, and specialized plastics drives major variable costs-iodine and gadolinium price swings added ~6-9% to raw-material spend in 2024, with Gd oxide at ~$80-120\/kg in late 2024; plastics for devices rose ~4% year-on-year. Manufacturing costs include clean-room ops and energy‑intensive synthesis; Guerbet's 2024 COGS margin pressure mirrored a ~3-5% rise in utilities and facility amortization. Efficient supply-chain management is critical to protect margins against 2025 inflation, where consensus CPI-linked input inflation is forecast ~4% for pharma inputs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales and Marketing Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMaintaining Guerbet's global sales force and attending international medical congresses costs tens of millions annually; Guerbet reported sales and marketing expenses of €176.8m in 2023, about 22% of revenue, reflecting travel, booth fees, and field salaries. Marketing also covers production of educational materials and digital platforms-Guerbet invested in digital engagement tools in 2024 to boost hospital contract wins and brand awareness.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Quality Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory compliance and quality control form a non‑negotiable cost line for Guerbet, with annual testing, global audits, and QMS maintenance across ~10 production sites costing an estimated €25-40m per year and staffing ~120 regulatory experts (2024 internal benchmark).\u003c\/p\u003e\n\u003cp\u003eNon‑compliance risk is severe-recalls or sanctions can exceed €100m and halt market access-so ongoing investment in audits, batch testing, and document control is mandatory.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e€25-40m annual compliance spend\u003c\/li\u003e\n\u003cli\u003e~120 regulatory staff (2024)\u003c\/li\u003e\n\u003cli\u003e~10 production sites under QMS\u003c\/li\u003e\n\u003cli\u003eRecall\/sanction risk \u0026gt;€100m\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and Distribution Overheads\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe transport of Guerbet's temperature-sensitive contrast agents drives significant logistics costs-cold chain handling adds up to 15-25% of COGS for specialty injectables, with cold-chain freight premiums of 20-50% versus standard freight in 2024 estimates.\u003c\/p\u003e\n\u003cp\u003eGlobal shipping and warehousing require tight QA and lead-time buffers; fuel price swings (jet fuel up ~18% in 2024) and complex import rules (EU MDR, US FDA, country permits) materially raise variability and contingency spend.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eCold-chain adds 15-25% of COGS\u003c\/li\u003e\n\u003cli\u003eCold freight premium 20-50% (2024)\u003c\/li\u003e\n\u003cli\u003eJet fuel +18% in 2024\u003c\/li\u003e\n\u003cli\u003eRegulatory compliance increases lead-time and cost variance\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGuerbet 2024: High R\u0026amp;D \u0026amp; S\u0026amp;M, costly cold‑chain and recall risk threaten margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpguerbet cost structure: r rev s compliance regulatory staff sites raw volatility added to input costs cold of cogs recall risk\u003e€100m.\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLine\u003c\/th\u003e\n\u003cth\u003e2024 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e€45-55m (12-15% rev)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eS\u0026amp;M\u003c\/td\u003e\n\u003ctd\u003e€176.8m (22%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance\u003c\/td\u003e\n\u003ctd\u003e€25-40m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold‑chain\u003c\/td\u003e\n\u003ctd\u003e15-25% COGS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/pguerbet\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales of Contrast Agents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe core revenue stream is volume sales of contrast media for CT, MRI and interventional procedures, sold largely via multi‑year hospital and imaging‑center contracts; Guerbet reported 2024 contrast sales of €710m, ~68% of group revenue. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Injection Systems and Consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuerbet earns major revenue from power injectors and high-margin disposables (syringes, tubing); consumables accounted for about 48% of product sales in 2024, driving recurring income since each item is single‑use per patient.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Solution Subscriptions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpguerbet is shifting revenue to annual saas fees for ai and data platforms which delivered an estimated in recurring carry gross margins above complementing contrast-agent sales. as hospitals digitize management expects this segment grow at cagr end-2025 materially raising share versus one-time device income.\u003e\n\u003c\/pguerbet\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eService and Maintenance Contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eService and maintenance contracts generate recurring revenue from post-sale agreements for maintenance and repair of Guerbet injection hardware, keeping hospital devices operational and compliant with safety and regulatory standards.\u003c\/p\u003e\n\u003cp\u003eIn 2025 Guerbet estimated these contracts deliver roughly 18-22% of equipment-related revenue, offering steadier cash flow and lower sensitivity to product sale cycles; uptime guarantees reduce hospital risk and support multi-year renewals.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRecurring revenue: 18-22% of equipment revenue (2025 est.)\u003c\/li\u003e\n\u003cli\u003eReduces sales volatility; multi-year renewals common\u003c\/li\u003e\n\u003cli\u003eSupports regulatory compliance and equipment uptime\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and Royalty Income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGuerbet occasionally licenses proprietary imaging agents and formulations, earning upfront fees plus royalties-typically single-digit to low-double-digit percent of licensee net sales-generating non-core revenue that supplemented 2024 group revenue (EUR 934m) and helped monetize IP beyond contrast media markets.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUpfront payments plus royalties (≈3-12% typical)\u003c\/li\u003e\n\u003cli\u003eTargets non-core markets, diversifies revenue\u003c\/li\u003e\n\u003cli\u003e2024 total revenue EUR 934m; licensing is a small but strategic stream\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGuerbet: Contrast agents €710M, consumables \u0026amp; SaaS growth fueling recurring revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGuerbet's core revenue is contrast agents (€710m in 2024, ~68% of group), plus consumables (≈48% of product sales in 2024) and devices; AI\/data SaaS brought an estimated €40m recurring in 2024 and targets 30-40% CAGR to 2025; service contracts supply ~18-22% of equipment revenue (2025 est.), and licensing adds small royalties (≈3-12%).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eContrast agents\u003c\/td\u003e\n\u003ctd\u003e€710m (2024), 68%\u003c\/td\u003e\n\u003ctd\u003eMulti‑year hospital contracts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables\u003c\/td\u003e\n\u003ctd\u003e≈48% of product sales (2024)\u003c\/td\u003e\n\u003ctd\u003eHigh repeat usage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSaaS AI\/data\u003c\/td\u003e\n\u003ctd\u003e≈€40m (2024)\u003c\/td\u003e\n\u003ctd\u003e70%+ GM, 30-40% CAGR to 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService contracts\u003c\/td\u003e\n\u003ctd\u003e18-22% equipment rev (2025 est.)\u003c\/td\u003e\n\u003ctd\u003eRecurring uptime guarantees\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\u003c\/td\u003e\n\u003ctd\u003eSmall share\u003c\/td\u003e\n\u003ctd\u003eRoyalties ≈3-12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57347299606859,"sku":"guerbet-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/guerbet-canvas-business-model.webp?v=1779140693","url":"https:\/\/valuechainanalysis.com\/products\/guerbet-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}